4. Pulmonary arterial hypertension (PAH) is categorized into 4 groups, with 1 being the mildest and 4 being the most severe.
Scleroderma patients with PAH may benefit from PDE-5 inhibitors as early therapy. Read more here.
4. Pulmonary arterial hypertension (PAH) is categorized into 4 groups, with 1 being the mildest and 4 being the most severe.
Scleroderma patients with PAH may benefit from PDE-5 inhibitors as early therapy. Read more here.